Camelia S. Sima

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Helena A. Yu, Maria E. Arcila, Natasha Rekhtman et al. · Clinical Cancer Research · 2013 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations

Paul K. Paik, Maria E. Arcila, Michael Fara et al. · Journal of Clinical Oncology · 2011 · 690 citations · Full text

Medicine, Genetics, Oncology +17

Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas

Kyuichi Kadota, Jun‐ichi Nitadori, Camelia S. Sima et al. · Journal of Thoracic Oncology · 2015 · 674 citations · Full text

Medicine, Oncology, Surgery +17

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima et al. · Clinical Cancer Research · 2010 · 625 citations · Full text

Medicine, Oncology, Pharmacology +17

American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes

Lee M. Ellis, David Bernstein, Emile E. Voest et al. · Journal of Clinical Oncology · 2014 · 439 citations

Medicine, Oncology, Cancer Pharmacology +5